The Big Picture in Four Lines
Sources: the Ozempic® (05/2026), Wegovy® (06/2026) and Rybelsus® (01/2026) prescribing information.
Nausea Leads on Every Label
Nausea was reported by 11% to 20% of people on Rybelsus®, about 16% to 20% on Ozempic® and 44% on the Wegovy® 2.4 mg injection. Each trial had its own population and dose, so these ranges describe each label rather than rank the brands.
Dose Increases Are the Common Trigger
All three labels say most nausea, vomiting and diarrhea happened during dose escalation. That is why some people notice the weeks after a step-up more than the weeks in between.
Most People Kept Taking It
Stopping because of stomach effects ranged from about 3% to 4% on Ozempic® to 4% to 8% on Rybelsus®. Placebo rates in those trials were about 1% or lower.
The Same Boxed Warning Applies
Every semaglutide label carries a boxed warning about thyroid C-cell tumors seen in rodents. Pancreatitis, gallbladder disease, kidney injury and allergic reactions also appear on each one.
Ozempic®, Wegovy® and Rybelsus® Compared
One row per brand and form. The doses are the label's trial arms, not a recommendation, and rates from different trials cannot be directly compared.
| Brand | Form | Approved uses | Nausea | Any stomach effect | Placebo (nausea / stomach) |
|---|---|---|---|---|---|
| Ozempic® | Weekly injection | Type 2 diabetes, including heart and kidney risk reduction | 15.8% to 20.3% | 33% to 36% | 6.1% / 15% |
| Wegovy® | Weekly injection (2.4 mg trials) | Weight management, heart risk reduction, MASH with moderate to advanced fibrosis | 44% | 73% | 16% / 47% |
| Wegovy® | Daily tablet (25 mg trial) | Weight management, heart risk reduction | Similar to the injection | Similar to the injection | Not compared here |
| Rybelsus® (and Ozempic® tablets) | Daily tablet | Type 2 diabetes, including heart risk reduction | 11% to 20% | 32% to 41% | 6% / 21% |
Ozempic® Injection
In placebo-controlled trials in adults with type 2 diabetes, nausea was reported by 15.8% to 20.3% of people on Ozempic® versus 6.1% on placebo. Any stomach effect was reported by about 33% to 36%, compared with about 15%.
Wegovy® Injection and Tablet
On the weekly 2.4 mg injection, nausea was reported by 44% of adults and any stomach effect by 73%, compared with 16% and 47% on placebo. The label says the 25 mg daily tablet showed similar types and frequency of common side effects.
Rybelsus® Tablet
In the Rybelsus® trials in adults with type 2 diabetes, nausea was reported by 11% to 20% versus 6% on placebo. Any stomach effect was reported by 32% to 41%, compared with 21%.
Why the Rates Are Not a Ranking
The Wegovy® trials enrolled adults with obesity or overweight at a higher dose, while the Ozempic® and Rybelsus® trials enrolled adults with type 2 diabetes. The labels note that rates from different trials cannot be directly compared.
Brand-by-Brand Detail
For the full Ozempic® table, read Ozempic® side effects. For the injection and tablet data on the weight management brand, read Wegovy® side effects.
Other Effects That Show Up on the Labels
On Rybelsus®, stomach pain was reported by 10% to 11% of people versus 4% on placebo, and decreased appetite by 6% to 9% versus 1%. Indigestion, gas, reflux and gastritis appear on all three labels at lower rates. The injection figures for other effects are in Ozempic® side effects and Wegovy® side effects.
| Rybelsus® side effect | Rybelsus® | Placebo |
|---|---|---|
| Stomach pain | 10% to 11% | 4% |
| Decreased appetite | 6% to 9% | 1% |
When to Call or Seek Emergency Care
Swelling of the face, lips, tongue or throat, trouble breathing, or severe stomach pain that will not go away need emergency care. Call your prescriber about vomiting or diarrhea that does not ease, signs of dehydration, vision changes, symptoms of low blood sugar, or upper stomach pain with fever, yellowing of the skin or eyes, or clay-colored stools. Each brand's full list is in Ozempic® side effects and Wegovy® side effects.
This is not a complete list and it is not medical advice: if something feels wrong, call.
From the makers of this guide
Follow Your Own Pattern, Whatever the Brand
Pep AI lets you rate symptoms such as nausea, constipation, headache, fatigue and injection-site pain for severity each day, from a built-in list of GLP-1 symptoms grouped by body area, plus your own. A daily check-in adds mood, energy and sleep quality. For weekly Ozempic® or Wegovy® shots, your side-effect trend sits next to the estimated level chart on the Dose tab.
- 01
Symptoms Rated by Severity
Pick from the built-in list or add your own, and rate how strong each one was that day.
- 02
Side-effect trend on the Dose tab
Your symptom trend over recent days, on the same tab as your logged doses.
- 03
Estimated level chart for weekly shots
For weekly Ozempic® or Wegovy® shots, an estimate from your logged doses and the label half-life, not a lab value. It is not built for daily tablets.
Key takeaways
- Nausea was reported by 11% to 20% on Rybelsus®, about 16% to 20% on Ozempic® and 44% on the Wegovy® 2.4 mg injection.
- All three labels say most nausea, vomiting and diarrhea happened during dose escalation.
- The Wegovy® label says its 25 mg tablet showed similar types and frequency of common side effects to the injection.
- Every semaglutide label carries the boxed thyroid C-cell tumor warning; the Ozempic® and Wegovy® guides hold the full warnings.
- The trials enrolled different people at different doses, so the rates cannot be directly compared.
Know which side effects are yours.
Pep AI logs your semaglutide shots or tablets, symptoms with severity, meals and weight, and makes a PDF of your doses, injection sites and weight. Download Pep AI on iPhone or Android.
Frequently asked questions
Keep reading
Sources
- Ozempic® (semaglutide) injection prescribing information and Medication Guide, Novo Nordisk / FDA (revised 05/2026)
- Wegovy® (semaglutide) injection and tablets prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
- Rybelsus® and Ozempic® tablets (semaglutide) prescribing information and Medication Guide, Novo Nordisk / FDA (revised 01/2026)
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program
This page summarizes the Ozempic® (revised 05/2026), Wegovy® (revised 06/2026) and Rybelsus® and Ozempic® tablets (revised 01/2026) prescribing information for semaglutide. It is general information, not medical advice, and does not replace your prescriber or pharmacist. Rates from different trials cannot be directly compared. Pep AI is not affiliated with or endorsed by Novo Nordisk. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026